Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) EVP Caryn Peterson sold 4,757 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $12.07, for a total value of $57,416.99. Following the completion of the sale, the executive vice president now owns 61,415 shares of the company’s stock, valued at approximately $741,279.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Gossamer Bio Stock Down 0.5 %
Shares of GOSS stock traded down $0.06 on Tuesday, hitting $12.01. 1,338,708 shares of the stock were exchanged, compared to its average volume of 1,047,753. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 7.44. The firm has a market capitalization of $1.13 billion, a P/E ratio of -3.95 and a beta of 0.95. The business has a 50-day moving average of $13.15 and a 200 day moving average of $10.35. Gossamer Bio, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $15.19.
Gossamer Bio (NASDAQ:GOSS – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.07). Equities analysts anticipate that Gossamer Bio, Inc. will post -2.77 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of GOSS. Vanguard Group Inc. boosted its position in Gossamer Bio by 1.2% during the first quarter. Vanguard Group Inc. now owns 5,654,742 shares of the company’s stock valued at $49,083,000 after purchasing an additional 67,283 shares during the last quarter. State Street Corp boosted its position in Gossamer Bio by 17.1% during the second quarter. State Street Corp now owns 3,875,194 shares of the company’s stock valued at $32,435,000 after purchasing an additional 567,264 shares during the last quarter. Federated Hermes Inc. boosted its position in Gossamer Bio by 19.0% during the first quarter. Federated Hermes Inc. now owns 3,526,478 shares of the company’s stock valued at $30,610,000 after purchasing an additional 564,236 shares during the last quarter. Emerald Advisers LLC boosted its position in Gossamer Bio by 10.1% during the first quarter. Emerald Advisers LLC now owns 1,949,577 shares of the company’s stock valued at $16,922,000 after purchasing an additional 178,658 shares during the last quarter. Finally, Kynam Capital Management LP boosted its position in Gossamer Bio by 80.2% during the first quarter. Kynam Capital Management LP now owns 1,832,704 shares of the company’s stock valued at $15,908,000 after purchasing an additional 815,847 shares during the last quarter. 67.57% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms recently commented on GOSS. The Goldman Sachs Group began coverage on Gossamer Bio in a report on Thursday, October 20th. They issued a “buy” rating and a $22.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Gossamer Bio in a research note on Wednesday, September 21st. They issued a “neutral” rating and a $17.00 target price for the company. Wedbush initiated coverage on Gossamer Bio in a research note on Monday, September 19th. They issued an “outperform” rating and a $24.00 target price for the company. Raymond James boosted their target price on Gossamer Bio from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Thursday, July 14th. Finally, HC Wainwright boosted their target price on Gossamer Bio from $20.00 to $25.00 in a research note on Thursday, October 13th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.82.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.